slides · global inventory
Problem Agitate Solution
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 26,550
Current window 21,211-21,240
Pages 885
Rows per page 30
Arc
21,211-21,240 of 26,550
08
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem1 hit
10
The slide uses a pie chart for segmentation and a timeline/number line for diagnostic age, followed by key clinical metrics.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · AgitateLoop · Mece Breakdown1 hit
11
Includes a biological process diagram showing intracellular vs plasma metabolism.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · SolutionLoop · Mece Breakdown1 hit
12
The chart shows a clear dose-response relationship between 1.0 mg/kg and 10.0 mg/kg doses, with statistical significance marked at early time points.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
13
The slide uses two distinct chart types (Kaplan-Meier survival curve and a time-series pharmacodynamic plot) to demonstrate drug efficacy.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
14
The slide outlines a two-part clinical trial structure with specific cohorts and patient criteria.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
15
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
25
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact and Next Steps1 hit
26
Includes footnotes detailing cash equivalents and share breakdown.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact and Next Steps1 hit
06
The slide uses a four-column layout to structure the disease overview.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Problem1 hit
08
The slide uses a process-oriented diagram to show how three distinct mechanisms of action (MOAs) combine to lead to a clinical outcome.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
Includes a schematic of the GalNAc-linker-RNAi construct and a bar chart illustrating the suppression of various HBV transcripts.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
15
The slide uses a bulleted list with custom circular icons to present clinical safety findings.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
16
Data presented at AASLD 2022.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
01
Bionomics | Results Presentation Deck | 27 slidesBionomics | Results Presentation Deck | 27 slides · Bionomics
Conference presentation Investor relations Beat · Problem1 hit
02
Bionomics | Results Presentation Deck | 27 slidesBionomics | Results Presentation Deck | 27 slides · Bionomics
Conference presentation Investor relations Beat · Problem1 hit
03
The slide uses a Gantt-style visualization to represent clinical trial progress.Bionomics | Results Presentation Deck | 27 slides · Bionomics
Conference presentation Investor relations Beat · Problem1 hit
04
Bionomics | Results Presentation Deck | 27 slidesBionomics | Results Presentation Deck | 27 slides · Bionomics
Conference presentation Investor relations Beat · Problem1 hit
05
The chart shows a reduction in alpha 2 band power when BNC210 is administered alongside nicotine compared to nicotine alone.Bionomics | Results Presentation Deck | 27 slides · Bionomics
Conference presentation Investor relations Beat · AgitateLoop · Before After1 hit
06
The study uses a CCK-4-induced panic attack model to demonstrate Proof of Mechanism (PoM).Bionomics | Results Presentation Deck | 27 slides · Bionomics
Conference presentation Investor relations Beat · AgitateLoop · Before After1 hit
07
The slide uses three distinct panels to show imaging and behavioral results.Bionomics | Results Presentation Deck | 27 slides · Bionomics
Conference presentation Investor relations Beat · AgitateLoop · Before After1 hit
08
The slide uses a numbered list structure to map specific PK benefits to supporting data charts.Bionomics | Results Presentation Deck | 27 slides · Bionomics
Conference presentation Investor relations Beat · AgitateLoop · Before After1 hit
09
The chart uses a layered pie/segmentation visual to show the total addressable population vs. the specific opportunity for BNC210.Bionomics | Results Presentation Deck | 27 slides · Bionomics
Conference presentation Investor relations Beat · AgitateLoop · Before After1 hit
10
Bionomics | Results Presentation Deck | 27 slidesBionomics | Results Presentation Deck | 27 slides · Bionomics
Conference presentation Investor relations Beat · Solution1 hit
104
Includes a specific deadline for proxy submission that precedes the actual shareholder meeting date.Sarissa Capital | Activist Presentation Deck | 109 slides · Sarissa Capital
Activist deck Activist investor Beat · Solution1 hit
105
This is a procedural slide for an activist campaign proxy fight.Sarissa Capital | Activist Presentation Deck | 109 slides · Sarissa Capital
Activist deck Activist investor Beat · Solution1 hit
106
Standard proxy solicitation disclosure slide.Sarissa Capital | Activist Presentation Deck | 109 slides · Sarissa Capital
Activist deck Activist investor Beat · Solution1 hit
107
Sarissa Capital | Activist Presentation Deck | 109 slidesSarissa Capital | Activist Presentation Deck | 109 slides · Sarissa Capital
Activist deck Activist investor Beat · Solution1 hit
108
Sarissa Capital | Activist Presentation Deck | 109 slidesSarissa Capital | Activist Presentation Deck | 109 slides · Sarissa Capital
Activist deck Activist investor Beat · Solution1 hit
109
Sarissa Capital | Activist Presentation Deck | 109 slidesSarissa Capital | Activist Presentation Deck | 109 slides · Sarissa Capital
Activist deck Activist investor Beat · Solution1 hit